Sarepta Therapeutics Inc (NASDAQ:SRPT) had its price target lifted by stock analysts at SunTrust Banks, Inc. from $30.00 to $31.00 in a report released on Thursday, StockTargetPrices.com reports. SunTrust Banks, Inc.’s price target would suggest a potential downside of 4.73% from the stock’s current price.
SRPT has been the topic of a number of other research reports. Royal Bank of Canada boosted their price target on shares of Sarepta Therapeutics from $98.00 to $106.00 and gave the company an “outperform” rating in a report on Friday, December 16th. Vetr upgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating and set a $34.53 price objective on the stock in a research note on Monday, March 20th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, February 16th. Cowen and Company reiterated an “outperform” rating and issued a $62.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, December 21st. Finally, Robert W. Baird reiterated a “buy” rating and issued a $102.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Sarepta Therapeutics has an average rating of “Buy” and a consensus target price of $56.74.
Sarepta Therapeutics (NASDAQ:SRPT) traded down 2.1515% during mid-day trading on Thursday, hitting $31.8399. The stock had a trading volume of 682,812 shares. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $63.73. The firm has a 50-day moving average of $30.62 and a 200-day moving average of $35.06. The stock’s market cap is $1.75 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, February 28th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.33) by $0.62. The firm had revenue of $5.42 million for the quarter, compared to analyst estimates of $4.86 million. During the same quarter in the prior year, the firm earned ($1.44) EPS. The firm’s revenue was up 333.6% compared to the same quarter last year. On average, analysts forecast that Sarepta Therapeutics will post ($2.50) EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in SRPT. BlackRock Advisors LLC increased its position in Sarepta Therapeutics by 488.2% in the third quarter. BlackRock Advisors LLC now owns 839,928 shares of the biotechnology company’s stock worth $51,580,000 after buying an additional 697,122 shares during the last quarter. Jennison Associates LLC increased its position in Sarepta Therapeutics by 86.6% in the third quarter. Jennison Associates LLC now owns 1,393,788 shares of the biotechnology company’s stock worth $85,593,000 after buying an additional 647,030 shares during the last quarter. Redmile Group LLC acquired a new position in Sarepta Therapeutics during the third quarter worth approximately $39,327,000. Norges Bank acquired a new position in Sarepta Therapeutics during the fourth quarter worth approximately $11,181,000. Finally, BlackRock Group LTD increased its position in Sarepta Therapeutics by 433.6% in the third quarter. BlackRock Group LTD now owns 412,069 shares of the biotechnology company’s stock worth $25,304,000 after buying an additional 334,842 shares during the last quarter. 76.75% of the stock is owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.